BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma develops medicines for patients with genetic diseases, with its main product being Attruby for a heart condition. It last closed at $76.80 on Nov 17, down 0.72% on the day. BBIO last reported earnings on Thu, Oct 29, 2026. The average 12-month price target from 8 analysts is $112.13 (+46.0% from the last close), with a high of $156.00 and a low of $91.00. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (8 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in BBIO, 50% of them bullish and 50% bearish. In the past 30 days there were 3 dark pool prints totaling $5.1M, the largest $2.0M.
Key Stats
Last 12 monthsNot reported for this period.
From BBIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 8 analysts who set a price target on BBIO in the past 90 days. The average target is $112.13, with a high of $156.00 and a low of $91.00, compared with the last close of $76.80.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | Morgan Stanley | Target raised | Buy | $88 → $91 |
| Nov 2 | Canaccord Genuity | Target raised | Buy | $106 → $108 |
| Oct 30 | TD Cowen | Target lowered | Buy | $110 → $100 |
| Oct 30 | Morgan Stanley | Target raised | Buy | $87 → $88 |
| Oct 21 | Morgan Stanley | Target lowered | Buy | $97 → $87 |
Technical Analysis
The stock is 4% above its 20 day and 9% above its 50 day average. It is 5% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 60). The nearest support is the Pivot at $76.22, and the nearest resistance the swing high (Sep 9) at $76.81.
| RSI (14) | 59.54 | Middle of its range | Neutral |
| MACD | 2.42 | Above its signal line | Bullish |
| Stochastic | 71.3 | Middle of its range | Neutral |
| ADX (14) | 38.5 | Trending up | |
| Williams %R | -37.9 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 43.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +3.7% | Change over 10 sessions | Bullish |
| ATR (14) | $2.66 | Typical daily range, 3.5% of price |
| RSI (14) | 55.40 | Middle of its range | Neutral |
| MACD | 0.49 | Above its signal line | Bullish |
| Stochastic | 54.0 | Middle of its range | Neutral |
| ADX (14) | 24.8 | Weak trend | |
| Williams %R | -38.8 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 15.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +6.0% | Change over 10 sessions | Bullish |
| ATR (14) | $6.12 | Typical daily range, 8.0% of price |
What happened before
See how BBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How BBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options Flow
90DNo whale options trades in BBIO in the last 90 days.
Dark Pool
30DBBIO Institutional Ownership
Full report →- ▲259 buying vs 225 selling
- ▲Held by funds +17.4 pts
- ▼Funds holding -11
- ▼Superinvestors: 2 added, 3 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 481 | 492 | −2.2% |
| In funds' top 10 | 12 | 12 | 0.0% |
| Held by funds | 124.6% | 107.2% | +17.4 pts |
| New / increased | 65 / 194 | 83 / 174 | +0.8% |
| Reduced / sold out | 150 / 75 | 168 / 77 | −8.2% |
| Put/call ratio | 6.03 | 0.31 | +1861.5% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BBIO is in one of them and how their past BBIO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BBIO in an article yet. Here's the latest on the wider market.
BBIO Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Nov 2, 2026 | Nov 10, 2026 | 8 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Oct 27, 2026 | Nov 10, 2026 | 14 d |
| Gilbert CisnerosD · CA | Sell (partial) | $1K – $15K | Sep 29, 2026 | Oct 12, 2026 | 13 d |
| Donald J TrumpExecutive branch | Buy | $1K – $15K | May 18, 2026 | Jul 1, 2026 | 44 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | May 11, 2026 | Jun 8, 2026 | 28 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About BridgeBio Pharma
BridgeBio Pharma is a biopharmaceutical company based in Palo Alto, California, that develops medicines for people with genetic diseases. Its main commercial product is Attruby, a treatment for a heart condition caused by transthyretin amyloidosis, sold in the United States. The same medicine is sold under another name in Europe and Japan through partners. The company is also developing treatments for other rare conditions, such as achondroplasia and muscular dystrophy, for patients, physicians and healthcare providers.
- Headquarters
- Palo Alto, CA






